Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Alpine Immune Sciences is raising $82,666,486.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mitchell Gold played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alpine Immune Sciences

Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases and cancer, collaborations with world-class partners, and a robust development pipeline.

To learn more about Alpine Immune Sciences, visit http://www.alpineimmunesciences.com/

Contact:
Mitchell Gold, Chief Executive Officer
206-788-4545
mitchell.gold@alpineimmunesciences.com
https://www.linkedin.com/in/gold-mitchell-a7b561a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved